192 related articles for article (PubMed ID: 32667739)
1. Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma.
Peng M; Wen Q; Wu X; Yu F; Liu W
Thorac Cancer; 2020 Sep; 11(9):2704-2708. PubMed ID: 32667739
[TBL] [Abstract][Full Text] [Related]
2. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.
Yang Z; Yang J; Chen Y; Shao YW; Wang X
Target Oncol; 2019 Aug; 14(4):369-374. PubMed ID: 31301016
[TBL] [Abstract][Full Text] [Related]
3. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
4. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
[TBL] [Abstract][Full Text] [Related]
5. Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis.
Chen Y; Wang S; Zhang B; Zhao Y; Zhang L; Hu M; Zhang W; Han B
Target Oncol; 2020 Jun; 15(3):337-345. PubMed ID: 32495159
[TBL] [Abstract][Full Text] [Related]
6. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
7. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
9. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
Nakao A; Hiranuma O; Uchino J; Sakaguchi C; Kita T; Hiraoka N; Ishizuka T; Kubota Y; Kawasaki M; Goto Y; Imai H; Hattori N; Nakatomi K; Uramoto H; Uryu K; Fukuda M; Uchida Y; Yokoyama T; Akai M; Mio T; Nagashima S; Chihara Y; Tamiya N; Kaneko Y; Mouri T; Yamada T; Yoshimura K; Fujita M; Takayama K
Oncologist; 2019 May; 24(5):593-e170. PubMed ID: 30651400
[TBL] [Abstract][Full Text] [Related]
12. BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review.
Li X; Wang S; Li B; Wang Z; Shang S; Shao Y; Sun X; Wang L
Target Oncol; 2018 Aug; 13(4):517-523. PubMed ID: 29907952
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
Peng X; Long X; Liu L; Zeng L; Yang H; Jiang W; Liao D; Li K; Wang J; Lizaso A; Mao X; Xu Q; Mansfield AS; Yang N; Zhang Y
Eur J Cancer; 2020 Dec; 141():199-208. PubMed ID: 33171317
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
[TBL] [Abstract][Full Text] [Related]
15. Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.
Roca E; Pozzari M; Vermi W; Tovazzi V; Baggi A; Amoroso V; Nonnis D; Intagliata S; Berruti A
Lung Cancer; 2019 Jan; 127():12-18. PubMed ID: 30642539
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
John T; Akamatsu H; Delmonte A; Su WC; Lee JS; Chang GC; Huang X; Jenkins S; Wu YL
Lung Cancer; 2018 Dec; 126():133-138. PubMed ID: 30527177
[TBL] [Abstract][Full Text] [Related]
17. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
[TBL] [Abstract][Full Text] [Related]
18. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation.
Wang S; Yan B; Zhang Y; Xu J; Qiao R; Dong Y; Zhang B; Zhao Y; Zhang L; Qian J; Lu J; Zhao R; Han B
Int J Cancer; 2019 Jun; 144(11):2880-2886. PubMed ID: 30474188
[TBL] [Abstract][Full Text] [Related]
19. Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
La Monica S; Minari R; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Galetti M; Digiacomo G; Riccardi F; Petronini PG; Tiseo M; Alfieri R
Target Oncol; 2019 Oct; 14(5):619-626. PubMed ID: 31502118
[TBL] [Abstract][Full Text] [Related]
20. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]